Biomedical Bonding has received a granted patent from the United States Patent and Trademark Office (USPTO). The invention relates to a primer composition that may be applied to tissue to increase bond strength between the tissue and a patch, filler, or a
supporting material. The primer comprises a dithiol component and an allyl containing component together with a photo initiator.
The primer is an important part of ™
Our IP protection is now broader and targets key geographical areas. We look forward to introducing our appreciated novel technology to the US market”, comments Evelina Mikaelson CEO Biomedical Bonding
For more information, please contact.
Evelina Mikaelson
CEO Biomedical Bonding AB
Phone:+46 763 422 824
Homepage: www.biomedicalbonding.com
About Biomedical Bonding AB
Biomedical Bonding AB is a Swedish MedTech company that develops cutting-edge medical adhesive fixators and novel surgical methodologies with focus on the ever-growing market of hard tissue restorations. The technological platform, Bonevolent™, is market disruptive and stands for a paradigm shift in personalized surgical interventions. BMB´s vision is to become the dominant global provider of unique adhesive products suited for fracture fixation and dental restoration market. BMB´s Bonevolent™ products are easy-to-use by clinicians, will increase patient safety, save costs and resources for health care and society as a whole. BMB is a privately held company headquartered in Stockholm, Sweden.
Comments